Coca-Cola Europacific Partners plc (NASDAQ: CCEP) — The Best Bottler in the System, Priced Like the Franchisor It Rents From

Independent equity research. Report date: 2026-07-04. As-of price ~$106.61 (2026-07-02), near the 52-week high of $109.73; 52-week low $84.95. Market cap ~$47.0B; enterprise value ~$57–58B; net debt €9,823M (~$10.7B). UK-domiciled foreign private issuer; reports in EUR under IFRS; files 20-F/6-K (not 10-K/10-Q). FY-end December; FY2025 20-F filed 2026-03-13; FY2025 results 6-K 2026-02-17; most recent update Q1 2026 trading update (2026-04-28). The Coca-Cola Company owns ~19–20% of CCEP.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The detailed analysis that follows is deliberately position-free; this opening is the single place a view is expressed.

Verdict: HOLD — the best-run bottler in the Coca-Cola system, at a price that already assumes it has stopped being a bottler. Not a short. Accumulate on weakness, not here. Fair-value zone broadly ~$82–$95 (≈17–19x comparable EPS of €4.11 ≈ ~$4.8, ~5% shareholder yield); add sub-$90, ideally sub-$85; trim/avoid-adding above ~$105 (≈22x, richest-ever). Conviction: medium.

Coca-Cola Europacific Partners is a genuinely excellent operator — the largest, best-diversified, developed-market-weighted Coca-Cola bottler on earth, with the best geographies of any listed anchor bottler, a fortress-adjacent A3/A- balance sheet deleveraged on schedule to ~2.7x, an ROIC that has climbed from ~6% to ~11% as the Amatil and Philippines deals integrated, negligible stock comp, returns-focused incentives, and a management team that did the textbook-correct thing: integrate, deleverage to target, then pivot to a real capital-return program (a first €1.0B buyback in 2025 and another €1.0B in 2026, on top of a ~50%-payout dividend). None of that is in dispute. The problem is the seat it occupies and the price you now pay for it. CCEP is structurally the junior, capital-heavy half of someone else’s franchise: The Coca-Cola Company owns the brands, sets the concentrate price on an incidence basis that claws back a share of every euro of price CCEP takes, holds a ~20% equity stake, and grants the exclusive territories on renewable, non-perpetual, performance-terminable 10-year agreements. That is why a superb bottler still earns only a ~13% operating margin and a ~10–11% ROIC — roughly WACC-plus-three — versus KO’s 28.7% blended / 59% concentrate margins and mid-teens ROIC. The market is currently paying a quality-compounder multiple (~22x comparable earnings, ~13x EV/EBITDA, composite 97.8th percentile of CCEP’s own history — richest ever on every metric, and a premium to fellow bottlers Coca-Cola HBC ~10.3x and KOF ~7.5x EV/EBITDA) for economics that are permanently capped by the franchisor.

The framing is quality-at-a-full-price / return-of-capital-masquerading-as-a-compounder, not value and not a falling knife. The 2022→2026 ~2.7x move was roughly half re-rating (EV/EBITDA ~9–10x → ~13x) and half earnings — and the re-rating leg is now spent. What the market is pricing correctly: the durability of Coca-Cola system demand, the diversification, the improving ROIC, the low-beta (0.29) defensive character, and the genuine capital-return inflection. What I think it is under-pricing: that this is still a low-single-digit organic grower whose entire algorithm leans on price/mix in a mature, weakening European consumer (Germany/France volumes already down on higher sugar taxes), against a rising ~26% tax rate, with a slice of every price increase leaking upstream to KO and a slice destroyed by regulation (sugar taxes, deposit-return schemes, EPR) — all landing on the bottler’s cost base, not the franchisor’s. Bullish trigger (flips me constructive): two-plus quarters proving the Philippines/Indonesia EM leg has inflected into a durable volume engine while European volume stabilizes and margins add 50–100 bps — genuine graduation from “bottler” to “quality staples compounder” that justifies the multiple. Bearish trigger: European volume stays negative and price/mix can no longer offset it (comparable-EPS growth slips below ~4%), the multiple mean-reverts toward the CCH/KOF 10–11x band, and a US holder eats an EUR/USD reversal on top. Because the beta is genuinely low, the bear case is a slow de-rate to flat-to-negative real return, not a crash — which is exactly why it is easy to overpay here. Tag: “A landlord’s multiple for a tenant’s economics.”

📈 Stock Price Action — Five-Year Event Map

CCEP has been one of the quietest one-way streets in consumer staples. The five-year arc is a near-uninterrupted low-volatility climb: a COVID crash to roughly ~$24–28 in March 2020, a grind through the low-$40s–low-$50s in 2021–2022, a dip back to ~$40 in the October-2022 European energy crisis, and then a relentless ~2.7x re-rating from that trough to ~$106.61 at 2026-07-02 — the current level, near the top of a 52-week range of $84.95–$109.73. Year-end closes tell the story cleanly: 2022 $50.2 → 2023 $62.6 → 2024 $74.0 → 2025 $89.7 → $106.6 now. With a realized beta of only ~0.29 and positive alpha (~+0.16), the stock has compounded like a low-vol bond-proxy while quietly delivering equity-like returns. (Source: AZI 5-year price CSV, accessed 2026-07-04.)

Cycle narrative. (1–2) The COVID drawdown and recovery mirror CCEP’s outsized away-from-home channel mix — the sharpest crash and one of the sharpest staples recoveries in the group; the cause attribution is interpretation, the price moves are fact. (3) The 2021 rise coincided with the Coca-Cola Amatil acquisition that created the APAC franchise and the “Europacific” identity, plus a general reopening-beta bid. (4) The 2021–2022 fade was a genuine European macro shock — energy-crisis recession fear and a weak EUR compressing the USD-quoted line — and marks the last time the stock was cheap on its own history. (5) The 2022–2024 leg is the core thesis in price form: pricing-led organic revenue (revenue €17.3B→€20.4B), margin recovery, and the Philippines (CCBPI) bolt-on re-rated a “cheap defensive bottler” into a “quality compounder.” (6) The FY2025 results on 2026-02-17 — net income up 37% to €1.94B, comparable EPS growth, and the inaugural €1.045B buyback — drove the spike to ~$103.5 by Feb-18. (7) The spring pullback to ~$90 was ordinary post-print digestion amid European consumer-softness chatter (m3 factor return read ~−15% raw as of 5/31). (8) The June–July rally, capped by a ~+6% two-day move on 1–2 July 2026 to a fresh high, is momentum without a confirmed single catalyst in the news feed — plausibly positioning ahead of H1 results and continued low-vol bid (interpretation). No price target, no recommendation, no support/resistance implied — this is price history and its most likely drivers.

1. Executive Summary

Coca-Cola Europacific Partners is the world’s largest independent Coca-Cola bottler by revenue — the capital-heavy, route-to-market half of the Coca-Cola system. It buys concentrate from The Coca-Cola Company (TCCC) and other brand owners, combines it with water, sweetener, CO₂ and packaging, and manufactures, distributes and merchandises finished non-alcoholic ready-to-drink beverages across 31 markets — a mature, profit-core Europe segment (Great Britain, Germany, France, Iberia, Benelux, the Nordics; ~74% of revenue) and a higher-growth API/Australia-Pacific-Indonesia + Philippines segment (~26%). FY2025 revenue was €20,901M (+2.3% reported), operating profit €2,792M (13.4% margin), net income €1,942M, comparable diluted EPS €4.11 (+6.2%). It is the product of three M&A waves: the 2016 merger that formed Coca-Cola European Partners, the 2021 Coca-Cola Amatil acquisition that added APAC (and the “Europacific” rename), and the February-2024 Coca-Cola Beverages Philippines deal (60% stake, ~$1.8B, with Aboitiz).

The defining structural fact is that CCEP sits in the subordinate seat of its own system. TCCC owns the trademarks, sets concentrate price on an incidence basis (concentrate cost rises with CCEP’s own revenue-per-case, so the franchisor recaptures a share of any pricing CCEP takes), holds a ~19–20% equity stake, and grants CCEP’s exclusive territories on 10-year, renewable, non-perpetual, performance-terminable franchise agreements. This is the entire economic architecture: it is why the world’s best bottler carries only a ~35% gross / ~13% operating margin and a ~10–11% ROIC, versus KO’s 28.7% blended / 59% concentrate operating margin and mid-teens ROIC (per The Coca-Cola Company’s disclosed segment margins, FY2025 10-K). CCEP owns the capital and the operational excellence; the profit pool flows up to the brand owner.

The moat is real but borrowed and capped. In Greenwald’s taxonomy, CCEP’s advantage is a regional cost/scale advantage — local distribution density fused to a legally exclusive franchise territory (~80 plants, >90% local production, ~4M outlets, a dense chilled route-to-market no sub-scale rival can replicate, ring-fenced by exclusivity). That density is genuine and produces the ~13% margin — the best geographies of any listed anchor bottler, superior to Coca-Cola HBC. But the brands, the concentrate price, the fastest-growing categories (energy: CCEP distributes Monster, it does not own it) and even the territory grant all belong to others; the moat protects the field, not the winnings. It is a durable position with capped economics.

Growth is mid-quality: bought-and-priced, not volume-driven. The ~6.5% four-year revenue CAGR is dominated by the Philippines consolidation plus price/mix atop a flat-to-declining European volume base (FY2025 total volume +0.2%, Europe −0.2%; Germany/France down on higher sugar taxes). The forward algorithm — ~3–4% revenue / ~7% operating profit / mid-single-digit comparable EPS — is credible but powered by margin, mix, efficiency and buybacks, not an owned volume engine, and it must overcome a rising ~26% tax rate and higher refinancing costs. The one genuinely high-quality growth asset is the Philippines/Indonesia per-capita runway, which management is deliberately conservative about (Indonesia declined double-digits in 2025).

Capital allocation is the standout strength. Management deleveraged from ~4.4x (post-Amatil) to its ~2.7x target, ran a disciplined bolt-on (CCBPI) at a sensible entry, kept SBC negligible (~€47M), tied long-term pay to comparable EPS and ROIC, and pivoted to shareholder returns: ~€2B of buybacks across FY2025–26 (all shares cancelled; count down to 443M) plus a growing ~50%-payout dividend. The only critique is timing — buying back a lot of stock at the richest own-history multiple in CCEP’s history.

Valuation is full, not bubble. At $106.61, CCEP trades at ~21–22x comparable earnings, ~13x EV/EBITDA, ~4.5% FCF yield, 2.25% dividend yield — the composite 97.8th percentile of its own multi-year history (P/S 99.8th, P/E 93.8th+), richest-ever on every metric, and a premium to direct bottler comps CCH (~10.3x EV/EBITDA) and KOF (~7.5x). The bottler discount to franchisor KO (~22–23x EV/EBITDA) is deserved and permanent — a ~10% ROIC business should trade at roughly half a ~mid-teens-ROIC one — so “cheaper than KO” is true but misleading; the honest question is whether CCEP deserves both its richest-ever re-rating and a premium to its own kind. An absolute low-WACC FCF perpetuity embeds only ~3–3.5% growth (beatable — hence not a short), but the easy re-rating money is made; forward return is now essentially the mid-single-digit algorithm plus ~5% shareholder yield, with the multiple a headwind if it mean-reverts. This article takes no position and sets no price target (the single exception is the author’s opening view above); the valuation, variant-perception and “what must be true” sections frame what the price requires and how each side falsifies.

2. Business Overview

What CCEP actually is. Coca-Cola Europacific Partners plc (NASDAQ: CCEP) is the capital-heavy, low-margin half of the Coca-Cola system — the world’s largest independent Coca-Cola bottler by net revenue. It buys concentrate from The Coca-Cola Company (TCCC) and other brand owners, combines it with water, sweeteners, CO₂ and packaging, and manufactures, distributes and merchandises finished non-alcoholic ready-to-drink (NARTD) beverages across 31 markets serving ~600 million consumers and ~4 million customer outlets, from ~80 plants, with >90% of product made locally (FACT; FY2025 20-F, filed 2026-03-13; DATA_PACK). This is the mirror image of the KO business model: where TCCC sells concentrate at ~61.6% gross / ~28.7% operating margin and lets bottlers finance the plants, fleets, coolers and commodity risk, CCEP is the bottler that finances all of that — which is why its operating margin is only ~13.4% and its ROIC ~10.5%, versus KO’s mid-to-high-teens ROIC (FACT; DATA_PACK; cross-read KO FY2025 report, 2026-06-11). CCEP is the finished-goods, route-to-market utility of the system, not the brand owner.

How it makes money — mechanically. CCEP earns a spread between the shelf price of a finished beverage and the sum of its input costs (concentrate + PET/aluminum/sugar + labor + distribution). Two structural facts define the economics. First, concentrate is priced by TCCC on an incidence basis — concentrate cost rises with CCEP’s own revenue per unit case (“As you know, our concentrate costs are tied to our revenue per unit case growth” — CFO Ed Walker, Q4/FY2025 call, 2026-02-17) (FACT). This means every euro of price/mix CCEP pushes through automatically raises its concentrate cost, so the brand owner claws back a share of any pricing CCEP takes — a structural tax on the bottler’s pricing power (INTERPRETATION). Second, CCEP owns the balance-sheet-heavy assets: ~€10.7B gross debt, tangible book value negative ~−€19/share (goodwill/intangibles from CCE/Amatil/Philippines deals exceed equity), and ~€750M annual capex (FACT; DATA_PACK).

Segments and geography. CCEP reports two segments (FY2025 20-F):

• Europe — €15,404M revenue (~74% of total; +1.3% YoY from €15,205M). Ten mature Western/Northern European markets: Great Britain, Germany, France, Belgium, Netherlands, Luxembourg, Iberia (Spain/Portugal/Andorra), Iceland, Norway, Sweden. This is the profit core: developed, high-per-capita, low-volume-growth.
• API (Australia, Pacific & Indonesia) + Philippines — €5,497M revenue (~26%; +5.0% from €5,233M). Australia, New Zealand, Pacific Islands, Papua New Guinea, Indonesia and — from February 2024 — the Philippines (60% controlling stake in Coca-Cola Beverages Philippines, ~$1.8B, with Aboitiz Equity Ventures). This is the growth/emerging-market leg: lower per-capita consumption, higher structural volume headroom, but also FX/macro volatility (FACT; DATA_PACK; 20-F).

Total FY2025 revenue €20,901M, operating profit €2,792M (13.4% margin), net income €1,942M (FACT; DATA_PACK).

The corporate history is a roll-up. CCEP is the product of three large M&A waves: (1) May 2016 merger of Coca-Cola Enterprises, Coca-Cola Iberian Partners and Coca-Cola Erfrischungsgetränke into “Coca-Cola European Partners”; (2) May 2021 acquisition of Coca-Cola Amatil (Australia/Pacific/Indonesia), which added the APAC leg and prompted the “Europacific” rename; (3) February 2024 Philippines (CCBPI) acquisition (FACT; DATA_PACK). The negative tangible book value and the ~€9.3–9.8B net debt are the balance-sheet residue of this acquisitive build (FACT).

The KO relationship — ownership and control are asymmetric. TCCC owns ~19–20% of CCEP (via European Refreshments and subsidiaries), which management frames as “alignment” (FACT; DATA_PACK). But the governing legal instruments are the bottler agreements, which have an initial term of 10 years, renewable for successive 10-year terms, and which TCCC may terminate “due to non-performance of the terms of the agreement” (FACT; FY2025 20-F). This is the single most important structural nuance in the whole thesis: CCEP’s exclusive territories are not perpetual and not unconditional — they are decade-length franchises, renewable at TCCC’s discretion and revocable for underperformance. The value-chain power sits clearly with the franchisor. (INTERPRETATION)

Brand portfolio. CCEP distributes TCCC’s trademarks (Coca-Cola, Coke Zero Sugar, Diet Coke, Fanta, Sprite; Powerade, Aquarius; smartwater, Chaudfontaine, BONAQUA; Costa Coffee RTD, Nestea, Fuzetea, Honest; Capri-Sun, Minute Maid, Oasis; Schweppes, Royal Bliss), distributes Monster/Reign/Relentless as Monster Energy’s route-to-market partner in its territories, and carries local jewels (Mezzo Mix, L&P, Lift). It also sells RTD alcohol — Jack Daniel’s & Coca-Cola and Absolut & Sprite (FACT; DATA_PACK; 20-F). Note that the brands CCEP sells are almost entirely owned by someone else — TCCC or Monster — which is the essence of its dependent position.

Revenue is recurring — behaviorally, not contractually. Demand is daily, low-ticket, habitual, geographically diversified across 31 markets and ~4M outlets, split between at-home (grocery/retail) and away-from-home (on-premise/immediate consumption) channels; the away-from-home/immediate-consumption channel carries higher margin per case and is a management focus (FACT/INTERPRETATION; Q4 2025 call). This recurring demand base is real and durable — but it is the category’s durability, largely created by TCCC’s brand marketing, not CCEP’s.

Verdict (Business Overview): CCEP is a large, well-run, geographically diversified beverage distribution utility that occupies the structurally subordinate half of the Coca-Cola value chain. It owns the capital and the operational execution; TCCC owns the brands, sets concentrate price on an incidence basis that recaptures a share of any pricing CCEP takes, holds a ~20% equity stake, and controls 10-year renewable franchise agreements. The business is high-quality as a bottler — record €20.9B revenue, rising margins and ROIC, strong cash generation — but it is definitionally the price-taker on brand and concentrate. Value capture in this system flows up to the franchisor.

3. Industry Dynamics

Two very different industries under one ticker. CCEP straddles a mature, saturated Western European NARTD market (74% of revenue) and a higher-growth, lower-per-capita Asia-Pacific/Southeast-Asian market (26%). They must be assessed separately.

Western Europe — mature, low-growth, retailer-dominated. Western European soft-drink volume is projected to grow only ~1–2% per year, constrained by demographic stagnation and a secular shift away from full-sugar CSDs; 2025 was “a challenging year… sharply increasing retail prices led to flat or declining volumes in key mature markets including… Europe” (FACT; Euromonitor / market data via web search, 2025). Per-capita consumption is already high (Germany ~142 L of non-alcoholic beverages/person in 2023; Central & Western Europe ~91 L soft drinks at-home in 2025), leaving little volume headroom — the region is a price/mix story, not a volume story (FACT; Statista/Euromonitor, 2025). CCEP’s own FY2025 Europe volume was soft, with “softer volumes in Germany and France, impacted by the higher sugar tax” (FACT; Q4 2025 call).

Retailer power is the defining structural feature in Europe — and it is adverse. Western European grocery is highly concentrated (Edeka, Rewe, Schwarz/Lidl-Kaufland, Aldi, Carrefour, Tesco, Ahold), and these buyers wield real leverage over branded suppliers, periodically delisting brands in price disputes. Private label is large and growing: private labels account for ~44% of all new product introductions in Western Europe, and in categories like water grew double-digits (e.g., private-label water +14% in 2023) as cost-pressed shoppers trade down (FACT; NIQ 2025; Euromonitor). For a bottler that must fund coolers, promotions and route-to-market to defend shelf space, concentrated retailers and cheap private label are a persistent margin governor. (INTERPRETATION)

Asia-Pacific / SE Asia — the growth leg, but volatile. Indonesia (~280M people) and the Philippines (~115M) have low per-capita CSD consumption and genuine volume headroom — the structural attraction of the Amatil/CCBPI deals. But 2025 exposed the volatility: “Indonesia had a challenging year with the macroeconomic slowdown impacting consumer demand” and the Philippines cycled “adverse weather” (FACT; Q4 2025 call). This leg offers the volume growth Europe cannot, at the cost of EM macro, FX and execution risk.

Regulation — a structural cost headwind that lands disproportionately on the bottler. Three regulatory vectors matter, and each is a bottler cost, not a brand-owner cost:

1. Sugar/excise taxes. Higher soft-drink taxes in GB and France directly hit FY2025 volumes and raised cost of sales; France’s sugar-tax increase was called out repeatedly as a 2025/2026 headwind (FACT; 20-F; Q4 2025 call). 50+ jurisdictions now tax sugar-sweetened beverages — a compounding, one-directional policy risk.
2. Deposit return schemes (DRS). DRS are being implemented across CCEP’s key European markets (Portugal, and rollouts across GB/Germany/others), imposing collection, handling and system costs on the packaging owner — i.e., the bottler (FACT; 20-F: “deposit return scheme implementation plans in CCEP’s key markets”).
3. Extended Producer Responsibility (EPR) / packaging & plastics rules. EPR regulation shifts packaging end-of-life costs onto producers; recycled-content mandates (rPET) raise input costs (FACT; 20-F). All three raise the bottler’s cost base — CCEP owns the PET, the cans, the collection logistics. TCCC, selling concentrate, is largely insulated. (INTERPRETATION)

Commodity cycle — the Marathon “Capital Returns” lens. A bottler’s COGS is dominated by PET resin, aluminum, sugar/sweetener and energy — cyclical commodities CCEP does not control. In a rising-commodity year, margins compress unless price/mix outruns input inflation (and incidence pricing then hands part of that price back to TCCC as higher concentrate cost). This is the opposite of a capital-light royalty: CCEP absorbs the commodity cycle so TCCC doesn’t. Applying Marathon’s supply-side test — does capital flood in to compete away returns? — the answer for the bottling layer is nuanced: new capital cannot enter a given exclusive territory (the franchise blocks it), so returns are not competed away by entrants; but returns are capped from above by the franchisor’s incidence pricing and from below by retailer power and commodity/regulatory costs. The bottler earns a regulated-utility-like return (ROIC ~10.5%, only modestly above cost of capital), not an excess return. (INTERPRETATION)

Where the profit pool sits. The single most important industry fact: in the Coca-Cola system, ~59% LatAm / ~28.7% blended operating margin accrues to the concentrate owner (KO), while the bottler earns ~13% (FACT; DATA_PACK; KO FY2025 report). The profit pool is heavily skewed to the brand/IP layer. CCEP operates the good product in a structurally attractive category but from the weaker position in the chain.

Verdict (Industry Dynamics): a structurally mediocre industry for the bottler — a good category played from the wrong seat. The NARTD category itself is attractive (durable habitual demand, rational branded competition, an EM volume runway). But the bottling layer of it is not: mature Western European volumes (~1–2%), concentrated retailers and rising private label capping pricing from below, a compounding regulatory cost load (sugar taxes, DRS, EPR) that falls on the packaging owner, unhedged commodity cyclicality, and — decisively — a franchisor that sets concentrate price on an incidence basis and captures the fat end of the profit pool. CCEP earns a utility-like ~10.5% ROIC because that is what this seat structurally yields. Good category, structurally capped economics.

4. Competitive Position

Name the moat — precisely, and honestly. In Greenwald’s (“Competition Demystified”) taxonomy, CCEP’s advantage is NOT a brand/intangible moat (it does not own the brands) and NOT a demand-side captivity moat at the consumer level (drinkers can buy Pepsi tomorrow). CCEP’s genuine advantage is a regional cost/scale advantage rooted in local distribution density, fused to an exclusive, legally-protected franchise territory — Greenwald’s third and strongest category, economies of scale within a bounded local market plus customer captivity of a kind. Concretely: within a given territory, CCEP runs the densest chilled route-to-market — the plants, the ~4M-outlet cooler and delivery network, the merchandising — at a scale no sub-scale rival can replicate profitably, and the exclusive franchise legally bars any other Coca-Cola bottler from entering. That density advantage is real and produces the ~13% margin. (INTERPRETATION)

But pressure-test it — the moat is shared and borrowed, not owned. Two facts cap the moat’s durability and value:

1. The exclusive territory is granted, not owned. The franchise agreements run 10-year initial terms, renewable for 10-year terms, and are terminable by TCCC for non-performance (FACT; 20-F). CCEP’s entire competitive protection is a contract it does not control and must continually earn. TCCC’s ~20% equity stake aligns interests today, but the power is TCCC’s — it can (and across the system, franchisors have) reshape territories, set concentrate price, and withhold renewal. This is a rented moat. (INTERPRETATION)
2. The moat protects the territory, not the economics. Even inside its exclusive fortress, CCEP’s returns are squeezed by incidence pricing above (TCCC), retailer/private-label power beside it, and commodity/regulatory costs below. A moat that guarantees you the field but caps your winnings at ~10.5% ROIC is a real but low-octane moat. (INTERPRETATION)

Direct comparison — vs. Coca-Cola HBC (the closest comp). Coca-Cola HBC is the other large listed Coca-Cola anchor bottler (Central/Eastern Europe, Russia-legacy, Africa, Nigeria), the #3 anchor bottler by volume vs CCEP’s #1 by revenue (FACT; web search / Wikipedia, 2025). CCEP operates richer, more-developed territories (Western Europe, Australia) with higher revenue per case and a higher operating margin (~13.4%) than HBC’s structurally lower net margin (~6% net) (FACT; Morningstar/web search, 2025). CCEP is the higher-quality bottler of the two — better geographies, better mix, larger scale — but both sit in the same structurally subordinate seat and earn bottler-level (not franchisor-level) returns. The comparison confirms the seat, not an escape from it. (INTERPRETATION)

vs. PepsiCo system. In CCEP’s core European markets, the PepsiCo system is the durable #2 in colas but generally sub-scale to Coca-Cola in the on-premise/immediate-consumption channels where CCEP’s cooler density is strongest. Competition is rational — share is contested on execution, innovation and marketing, not destructive price wars — which protects category economics. But Pepsi’s snack diversification (Frito-Lay) is a category hedge CCEP wholly lacks; CCEP is a pure-play beverage bottler, maximally exposed to sugar-tax/health drift with no snack offset. (INTERPRETATION)

vs. energy (Red Bull, Monster) and RTD alcohol. In energy — the category’s fastest grower — CCEP participates as Monster’s distributor, not as owner (Monster volumes +~20% in 2025, +200 bps share; +75,000 coolers placed) (FACT; Q4 2025 call). This is incrementally good (CCEP rides the growth) but reinforces the pattern: CCEP’s growth engines are other companies’ brands. Red Bull remains the independent #1 energy brand outside CCEP’s control. RTD alcohol (Jack Daniel’s & Coca-Cola) is a genuine new white-space where CCEP’s distribution actually is the differentiator. (INTERPRETATION)

vs. private label. Private label is the real bottom-up threat in mature Europe (~44% of new-product launches; double-digit growth in water) — it attacks the value end and pressures branded shelf space and promotions (FACT; NIQ 2025). CCEP’s defense is brand pull (TCCC’s, not its own) plus cooler/immediate-consumption placement where private label is weak. The immediate-consumption channel is where CCEP’s density moat genuinely holds; the at-home multipack channel is where it is most contested. (INTERPRETATION)

Route-to-market density is the one thing CCEP genuinely owns. The defensible asset is the physical last mile: ~80 local plants, >90% local production, ~4M outlets, hundreds of thousands of coolers, and the logistics/merchandising to keep product cold and present at the point of impulse. This is expensive, slow to build, and territory-specific — a real barrier to a would-be entrant (though not to the franchisor). It is why CCEP, not a generic 3PL, holds the franchise. (INTERPRETATION)

Verdict (Competitive Position): a real but borrowed and capped moat — regional distribution density inside an exclusive franchise, owned at the franchisor’s pleasure. CCEP has a genuine, financially-evident local-scale/density advantage that no sub-scale rival can replicate, legally ring-fenced by exclusive 10-year territories — the best geographies of any listed Coke bottler, superior to Coca-Cola HBC. But it is not a durable owned moat: the brands, the concentrate price, the growth categories (energy) and even the territory grant all belong to others (TCCC, Monster), and the exclusive franchise is renewable-not-perpetual and revocable for non-performance. CCEP is the strongest player in a structurally subordinate role. Durable position, capped economics.

5. Growth History and Forward Opportunities

The headline growth is real but heavily M&A-built. Revenue rose from €17,320M (2022) → €18,302M (2023) → €20,438M (2024) → €20,901M (2025) — a ~6.5% CAGR (FACT; DATA_PACK). But decompose it honestly:

• The 2023→2024 jump (+€2,136M, +11.7%) is dominated by the February 2024 Philippines (CCBPI) consolidation, not organic momentum. CCBPI added a full new operating geography; on management’s adjusted comparable basis (which pro-formas the Philippines into the prior-year base), underlying growth was far lower (FACT/INTERPRETATION; 20-F; Q4 2025 call, which explicitly presents “adjusted comparable… as if the Philippines transaction had occurred at the beginning of last year”).
• The 2024→2025 step (+€463M, +2.3% reported) is almost entirely price/mix, not volume: comparable volume +2.4% and revenue per unit case +1.6% on the year, with the volume itself skewed to APS/Philippines while Europe volume was soft (Germany/France down on sugar tax) (FACT; Q4 2025 call; DATA_PACK).

So the four-year revenue build is: ~one large acquisition (Philippines) + price/mix + a modest, geographically-uneven volume contribution, with the mature European core essentially flat-to-down on volume. This is the classic staples pattern — acquired growth plus pricing masking developed-market volume stagnation — the same pattern as the KO franchisor, but with thinner margins to show for it. (INTERPRETATION)

Quality flag: pricing growth is partially recaptured by the franchisor. Because concentrate is priced on incidence, CCEP’s +1.6% revenue-per-case pricing automatically raised its concentrate cost (“driving higher concentrate costs through the incidence pricing model”) (FACT; Q4 2025 call). Price/mix growth is therefore lower-quality for the bottler than the same growth would be for the brand owner — a portion leaks upstream. (INTERPRETATION)

Forward drivers, ranked by conviction:

1. Philippines + Indonesia per-capita runway (highest structural conviction, highest execution risk). These low-per-capita EM markets are the genuine multi-year volume asset. Management expects “Indonesia to grow this year, both on volume and revenue” and a “more normalized outlook for the Philippines” after weather/macro headwinds (FACT; Q4 2025 call). Damian Gammell flagged “much bigger ambition… for [Indonesia]… sustainably impacting our long-term revenue algorithm” — but explicitly has not baked material upside into guidance, telling investors he wants “a good few quarters under our belt” first (FACT; Q4 2025 call). Conviction on the runway; caution on the timing — 2025 proved these markets are volatile. (INTERPRETATION)
2. Energy (Monster) + no-sugar mix shift (high conviction). Monster grew ~20% and gained >200 bps share in 2025; Coke Zero Sugar and single-serve PET drove European mix. This is the best organic growth CCEP has — but it is distributed growth on others’ brands, and no-/low-sugar is also the regulatory-hedge that protects volume against sugar taxes (FACT; Q4 2025 call). (INTERPRETATION)
3. Revenue Growth Management (RGM) + away-from-home/immediate consumption (medium-high). Pack-price architecture, promotional optimization, affordability packs and cooler placement (immediate consumption where margins are richest). More a margin/quality-of-pricing lever than a volume lever. (INTERPRETATION)
4. RTD alcohol (Jack Daniel’s & Coca-Cola, Absolut & Sprite) — genuine white space (medium). A category where CCEP’s distribution actually is the differentiator, and APS ex-alcohol already grew 7% (“its strongest growth for many years”) (FACT; Q4 2025 call).
5. Digital B2B + AI/SAP S/4HANA + efficiency programs (medium, margin-side). >€900M invested in “capacity, coolers, technology and digital”; ongoing efficiency programs to offset cost inflation; a margin/productivity story, not a top-line one (FACT; Q4 2025 call). Note incremental operating margin ran a strong ~55% in FY2025 (DATA_PACK).

Management’s forward algorithm. CCEP guides FY2026 to revenue +3–4% (“slightly below” the midterm) and operating profit +~7%, with the midterm algorithm framed as ~4% revenue / ~7% profit, “sustainable and achievable over the midterm” (FACT; Q4 2025 call). Growth is expected to be volume-plus-price, with the profit line out-growing revenue via mix, operating leverage and efficiency programs — i.e., margin expansion, not volume acceleration, is the primary earnings driver. Buttressed by a €1B annual buyback and rising dividend (FACT; DATA_PACK; Q4 2025 call), reported EPS growth will exceed operating growth.

Quality assessment. This is mid-quality growth for a bottler. In its favor: it is diversified (31 markets), self-help-heavy (RGM, efficiency, mix, buybacks all controllable), and carries a genuine EM volume option (Philippines/Indonesia). Against it: the mature-Europe core (74% of revenue) is volume-stagnant-to-declining; the biggest recent revenue jump was bought (Philippines); the pricing that drives most European growth is partially recaptured upstream by incidence concentrate pricing and partially destroyed by sugar taxes; and the best organic growth categories (energy, no-sugar) are TCCC’s/Monster’s brands, not CCEP’s. The earnings algorithm leans on margin expansion and buybacks more than on unit growth — durable, but not the compounding of a business that controls its own demand. (INTERPRETATION)

Verdict (Growth): mid-quality, self-help-and-M&A-driven growth with a real but back-loaded EM volume option. Revenue has compounded ~6.5%, but the mix is unflattering: a large acquisition (Philippines) plus price/mix, atop a flat-to-declining mature European volume base, with a slice of the pricing leaking back to the franchisor and a slice destroyed by sugar taxes. The forward algorithm (~4% revenue / ~7% profit) is credible and largely within management’s control — but it is powered by margin, mix, efficiency and buybacks, not by a volume engine CCEP owns. The Philippines/Indonesia per-capita runway is the one genuinely high-quality growth asset, and management is deliberately conservative about it. Durable, defensible, mid-single-digit — but capped, franchisor-dependent growth, not a compounder’s growth.

6. Financial Quality

Verdict up front: CCEP is a good-but-not-great business whose economics are improving with scale, but the improvement is narrower and more leverage-flattered than the headline ROE suggests. It is a low-gross-margin, asset-heavy, price-taking bottler sitting on the capital-intensive half of the Coca-Cola system, earning a mid-teens comparable ROIC on a book that is entirely intangible. Cash generation is real and consistent; returns on tangible capital are respectable for a bottler; but the 22% ROE is a leverage-and-goodwill artifact, not evidence of a KO-class franchise economic engine.

6.1 Revenue composition — mostly bought, not grown

FY2025 revenue was €20,901m, +2.3% reported / +2.9% comparable FX-neutral (FY2025 results 6-K, 2026-02-17, sec.gov/Archives/edgar/data/1650107/000165010726000007). The multi-year growth arc is dominated by acquisitions, not organic volume:

• FACT: Revenue went €17,320m (FY22) → €18,302m (FY23) → €20,438m (FY24) → €20,901m (FY25). The FY23→FY24 step (+€2.1bn, +11.7%) is almost entirely the Feb-2024 consolidation of Coca-Cola Beverages Philippines (CCBPI), not underlying demand (data pack; 20-F FY2025 segment note).
• FACT: Organic volume is roughly flat. FY2025 total comparable-FXN volume +0.2%, with Europe volume −0.2% and API/APS carrying the group (FY2025 results 6-K). Q1-2026 total volume +0.8%, Europe +1.3%, APS −0.3% — and Q1 was flattered by six extra selling days (Q1-2026 trading update 6-K, 2026-04-28).
• INTERPRETATION: Top-line growth is price/mix, not cases. Revenue-per-unit-case rose ~+2.9% comparable FXN in FY25 (results 6-K). This is the classic staples playbook — take price, hold volume — and it works while inflation is elevated, but it is not volume-driven compounding. When pricing normalizes, a low-single-digit organic grower is what remains.

6.2 Margins — structurally thin, cyclically improving on operating leverage

• FACT: Gross margin is stuck in a 35–37% band (35.9% / 36.7% / 35.3% / 35.6% FY22–25). This is the tell of the business model: KO keeps the high-margin concentrate economics (KO blended operating margin ~28.7%, LatAm concentrate operating margin ~59%; see KO_2026-06-11 report). CCEP buys concentrate, adds sugar/PET/aluminium/labour, and sells a physical case. It will never carry a franchisor’s gross margin.
• FACT: Operating margin expanded to 13.4% reported (comparable operating profit €2,808m, +7.1%) in FY2025 from 12.4% in FY24 (results 6-K; data pack). Comparable operating profit after tax attributable to shareholders €2,043m (FY24 €1,967m).
• FACT / the “55% incremental margin” claim: On +€463m of reported revenue FY24→FY25, reported operating profit rose €257m (€2,535m→€2,792m) — a ~55% incremental operating margin in the year. INTERPRETATION: this is genuine operating leverage (productivity/efficiency programmes, Amatil synergy tail, mix), but it is a one-year, cycle-favourable figure, not a run-rate. FY2026 guidance is more honest about the steady state: revenue +3–4%, cost-of-sales-per-case +~1.5%, operating profit +~7% (results 6-K) — i.e. ~2–3 points of incremental margin, not 55. Do not extrapolate the 55%.

6.3 Returns on capital — the ROE/ROIC gap is the whole story

• FACT: ROE 22.0% (FY25) vs comparable ROIC 11.5% / reported ROIC 10.9% (results 6-K), the latter +70bps yoy and up from ~6.1% in 2020 (data pack ROIC walk: 6.1→7.1→8.6→8.9→9.3→10.5→~11%).
• INTERPRETATION — is the ROIC improvement real or a goodwill/mix illusion? It is partly real and partly mechanical:
  • Real: as Amatil (2021) and CCBPI (2024) integrate and synergies land, NOPAT rises against a roughly fixed invested-capital base, and the deleveraging (below) lowers the drag. Rising ROIC on a stable capital base is the correct signal to watch, and it is genuinely trending up.
  • Mechanical/flattered: the ~11-point gap between ROE (22%) and ROIC (11%) is almost entirely financial leverage (net debt €9.8bn, debt/equity ~1.3x) plus the fact that book equity is inflated by acquisition intangibles. ROE is high because the equity base is thin relative to a debt-funded, goodwill-heavy balance sheet — not because incremental capital earns 22%. The number that matters, ROIC ~11%, is only modestly above CCEP’s ~7% WACC — a positive but unspectacular spread for a “wide-moat system” narrative.
• ASSUMPTION: WACC ~6.5–7.5% (investment-grade A3/A- issuer, low 0.29 realized beta, ~4% blended cost of debt). ROIC-minus-WACC ≈ +3–4 points. This is value-creating but thin — the bottler earns its keep, it does not mint it.

6.4 Cash conversion and capex intensity — watch the “free cash flow” definition

• FACT: Operating cash flow has been steady at €2.8–3.1bn (€2,953m FY25). Net income €1,942m → OCF/NI ~1.5x, healthy (D&A €923m, disciplined working capital).
• CAUTION / correction to the data pack: The data pack’s “FCF ~€2.2bn (OCF−capex)” overstates the company’s own measure. CCEP reports comparable free cash flow of €1,836m for FY2025 (results 6-K), because it (a) counts capex including leases and (b) deducts lease principal. FY2026 guidance makes the capital intensity explicit: capex ~5% of revenue including leases (~€1.0bn+), versus the €750m PP&E-only capex line the data pack used (~3.6% of revenue). INTERPRETATION: true economic capital intensity is closer to ~5% of revenue, and the right FCF number is ~€1.8bn, not €2.2bn. On a ~$47bn / ~€40bn market cap, comparable FCF yield is ~4.5%, not 5.3%. Still solid, but present the conservative figure.
• FACT: A bottler is asset-heavy by nature (plants, fleet, coolers, PET lines): PP&E €6,155m. This is the price of owning the capital-intensive half of the value chain — contrast KO, which is ~asset-light on concentrate. Capex intensity ~5% is higher than KO’s economic burden relative to the margin it supports.

6.5 Negative tangible book — an accounting artifact, not a red flag (but not nothing)

• FACT: Balance sheet carries Intangible assets €12,490m + Goodwill €4,536m = €17.0bn against total equity €8,303m (20-F FY2025 balance sheet). Tangible equity ≈ −€8.7bn, or ~−€19/share (data pack TBVPS −€19.13). Total assets €29,872m; total borrowings €10,694m; NCI ~€1.2bn (the 40% CCBPI minority held with Aboitiz).
• INTERPRETATION: Negative tangible book is normal and expected for an acquisitive franchised bottler. The €12.5bn of intangibles are overwhelmingly indefinite-lived franchise/bottling rights — the perpetual, effectively-renewable agreements with KO that are the business. They are not amortized, they are not saleable separately, and their carrying value is what CCEP paid to consolidate CCE, Amatil and CCBPI. This is not a solvency issue: the company is investment-grade (Moody’s A3 / Fitch A-, stable), interest cover ~10x, and generates €1.8bn+ of cash annually.
• BUT be direct about what it means: (1) book equity is not a downside anchor — there is no tangible asset backing; valuation rests entirely on the durability of the KO franchise relationship and the cash it throws off; (2) the intangibles are an impairment surface — a structural volume decline in a major territory (Indonesia is already weak) or a franchise-terms deterioration could force a write-down that vaporizes reported equity, as the €12.5bn is the accumulated M&A premium; (3) “P/B 5.78x, 99.8th percentile” (data pack) is a meaningless valuation metric here — ignore it. OPEN QUESTION: what discount rate / terminal volume assumptions underpin the annual goodwill/franchise-rights impairment test, and how much headroom exists in the weak Indonesia and low-growth European CGUs?

Financial-quality verdict: Economics do improve modestly with scale — ROIC is genuinely trending from ~6% to ~11% as acquisitions integrate and leverage falls, and operating leverage is real. But this is a thin-margin, capital-intensive, price-taking business whose eye-catching 22% ROE is manufactured by leverage and an all-intangible book, not by franchise-grade unit economics. The correct summary numbers are ~35% gross margin, ~13% operating margin, ~11% ROIC (≈3–4 pts over WACC), ~€1.8bn comparable FCF (~4.5% yield), ~5% capex intensity. Good business, structurally subordinate to its franchisor, priced (Section 10) as if it were the franchisor.

7. Capital Allocation

Verdict up front: This is the strongest part of the CCEP story. Management inherited a levered balance sheet from the Amatil deal, deleveraged on schedule to its ~2.7x target, ran a disciplined bolt-on (CCBPI) at a sensible entry, and has now pivoted credibly to shareholder returns — a first material buyback in FY2025 plus a fresh €1bn programme — while holding a ~50% dividend payout. Incentives are aligned to the right metrics. The one debate is whether buying back stock at a record 97th-percentile own-history valuation (Section 10) is the best marginal use of that cash. On the Marathon capital-cycle lens, management is behaving well; the price it is paying for its own equity is the question.

7.1 The deleveraging story — executed as promised

• FACT: Net-debt-to-comparable-EBITDA fell from ~4.4x post-Amatil (2022) to 2.7x at FY2025 (20-F FY2025: “net debt to comparable EBITDA is 2.7x”; net debt €9,823m / comparable EBITDA €3,700m). Correction to data pack: the leverage ratio is 2.7x, not 2.5x — the company states 2.7x for both FY2024 and FY2025 (FY25 net debt €9,823m vs FY24 €9,672m; comparable EBITDA €3,700m vs €3,524m). Total borrowings actually fell €11,331m→€10,694m yoy.
• INTERPRETATION: Reaching and holding the ~2.5–3.0x target range is exactly the discipline you want after a debt-funded acquisition spree. Interest coverage ~10x (EBIT/interest) and the A3/A- ratings confirm the balance sheet is now comfortably within investment-grade tolerances. Deleveraging is effectively complete — which is precisely why the buyback could start.

7.2 M&A record — two big deals, both defensible, integration the swing factor

• Coca-Cola Amatil (May 2021, ~$6.6bn / ~€5.6bn, APAC): transformed CCE-Iberia-Erfrischungsgetränke into a genuinely global bottler and is the source of most of the goodwill/intangibles. INTERPRETATION: strategically sound (diversified out of a low-growth, regulation-heavy European base into higher-growth APAC), and the FY22–25 ROIC climb is substantially the Amatil synergy tail landing. Price paid was full but not egregious for a scarce, KO-blessed asset.
• Coca-Cola Beverages Philippines / CCBPI (Feb 2024, ~$1.8bn for a 60% controlling stake, alongside Aboitiz Equity Ventures 40%): entry into a large, under-penetrated, hot-climate, young-demographic market. INTERPRETATION: the right kind of bolt-on — a growth market at a bottler multiple, with a strong local partner de-risking execution. But integration is unproven and the near-term read is mixed: FY2025 SEA was “flat with growth in the Philippines (cycling FY24 +11.0%) offset by double-digit decline in Indonesia” (results 6-K). The Philippines is delivering; Indonesia is the drag. OPEN QUESTION: what synergy/margin trajectory does CCBPI reach by FY2027, and is the 40% NCI structure a future full-buyout call on more capital?
• FACT: The 20-F explicitly notes “no cost savings or synergies were contemplated” in the acquisition accounting adjustments — i.e. the reported one-offs are transaction/step-up items, and synergy upside is incremental to the base.

7.3 The pivot to buybacks — new, credible, but at a rich price

• FACT: FY2025 was the first year of material repurchases: €1,045m executed (data pack; 20-F). CCEP then announced a further €1bn programme on 17-Feb-2026, running 18-Feb-2026 to ~end-Feb-2027, all shares cancelled (buyback 6-K, 2026-02-17). Status (verified): tranche 1 of €500m completed 24-Apr-2026; tranche 2 (~€500m) commenced 6-Jul-2026 (buyback update 6-K, 2026-07-02, sec.gov/Archives/edgar/data/1650107/000165010726000076). Goldman Sachs acts as riskless principal.
• FACT: Share count is already shrinking: 443.2m ordinary shares at the May-2026 AGM (AGM results 6-K, 2026-05-29) vs ~456m diluted FY2025 — the cancellations are real, not offset by dilution.
• INTERPRETATION: Cumulative ~€2bn of buybacks across FY2025–FY2026 on top of the dividend is a genuine capital-return inflection, appropriate now that leverage is at target and FCF is stable. The skeptical flag: management is buying back stock at the richest valuation in CCEP’s history — composite 97.8th own-history percentile, P/E 93.8th (data pack). Buybacks at a record multiple destroy per-share value versus buybacks in a drawdown; a bottler compounding EPS in the mid-single-digits does not obviously clear its own cost of equity when repurchasing at ~18–21x. This is good governance, mediocre timing. Marathon lens: management is returning capital rather than chasing empire-building M&A (correct, anti-capital-cycle behaviour) — but is paying a cyclical-high price for its own shares.

7.4 Dividend and SBC

• FACT: DPS €1.67 (FY22) → €1.83 → €1.98 → €2.04 (FY25), at a ~50% payout of comparable EPS (results 6-K). Progressive, well-covered, ~2.25% yield.
• FACT: Stock-based compensation is trivial — ~€47m/yr (data pack), well under 0.25% of revenue and immaterial to dilution. This is an old-economy bottler, not an SBC-flattered growth name. A refreshing contrast to the software comps elsewhere in the book.

7.5 Incentive alignment — aligned to the right things

• FACT (20-F FY2025 remuneration report): Long-term incentive (PSU) metrics are comparable diluted EPS, comparable ROIC, and a CO₂e-reduction-per-litre modifier (20-F: “EPS (A) … FY2027 target 4.28 / 4.80 / 5.17; ROIC (B) …”). The FY2027 LTIP EPS target range of €4.28–€5.17 comparable diluted EPS implies management is underwriting only ~mid-single-digit comparable-EPS CAGR off the €4.11 FY2025 base — a realistic, not heroic, plan.
• INTERPRETATION: Anchoring long-term pay to comparable EPS and ROIC is exactly right for a leveraged, acquisitive bottler — it rewards returns-on-capital discipline, not just growth or size, and directly guards against value-destructive M&A. SBC is small, so the incentive is about behaviour, not dilution. Modest concern: “comparable” EPS strips acquisition/integration costs (the reported-vs-comparable gap, Section 8), so management is partly graded on the adjusted number — standard, but worth monitoring that adjustments stay honest.

Capital-allocation verdict: Management has allocated capital intelligently and in the correct sequence — integrate, deleverage to target, then return cash — with disciplined bolt-on M&A, a growing well-covered dividend, negligible SBC, and returns-focused incentives. The only real critique is buying back a lot of stock at a record own-history multiple; the process is right even where the entry price is not. Net: a clear positive for the thesis.

8. Changes and Headwinds — Last Two Years

Verdict up front: The last two years strengthened the business’s shape (bigger, more geographically balanced, deleveraged, now returning cash) while the environment softened (flat-to-negative European volume, weak Indonesian consumer, rising packaging regulation, and a stepping-up tax rate). On balance the structural moves are net-positive and the headwinds are manageable and mostly already in the numbers — but they cap the growth algorithm at low-single-digit organic, which matters at today’s valuation.

8.1 6-K material-event timeline (SEC sweep)

CCEP is an FPI: it files a 20-F annually (FY2025 filed 2026-03-13) and 6-Ks for interims, monthly buyback/holdings notices, PDMR dealings and results. Key events in the trailing window (SEC EDGAR, CIK 1650107):

• Feb 2024 — CCBPI Philippines acquisition closes (60% stake, with Aboitiz); APAC segment renamed API/APS; consolidation drives the FY24 revenue step-up.
• 17-Feb-2026 — FY2025 preliminary results (comparable EPS €4.11, +6.2%); first €1bn buyback programme announced; DPS €2.04; FY26 guidance issued.
• 28-Apr-2026 — Q1-2026 trading update: revenue €5,001m +8.5% reported / +6.7% comparable FXN, guidance reaffirmed.
• 24-Apr-2026 — buyback tranche 1 (€500m) completed.
• 28/29-May-2026 — AGM; all 31 resolutions passed; interim dividend approved; 443.2m shares in issue.
• 02-Jul-2026 — buyback update: tranche 2 (€500m) to start 6-Jul-2026.
• 2024 — UK listing transferred to the Equity Shares “Commercial Companies” category; CCEP entered the FTSE UK Index Series in March 2025 (results 6-K) — a technical positive for index demand.
• INTERPRETATION: No adverse material events (no profit warning, no cyber incident, no covenant/liquidity stress, no restatement, no auditor change) surfaced in the corpus. The 6-K flow is dominated by routine monthly buyback and holdings notices — a benign, boring tape, consistent with the low-vol staples profile.

8.2 Insider read (Form 144 / PDMR) — routine, no conviction signal either way

• FACT: The 5-year corpus holds 52 Form 144s (proposed-sale notices), skewed heavily to the recent run-up: 5 (2023), 7 (2024), 21 (2025), 19 (2026 YTD). Individual sizes are small — e.g. a 23-Jun-2026 filing for 1,000 ordinary shares (~$98k). PDMR dealing 6-Ks are equity-award grants/vesting (e.g. CEO Damian Gammell PSU grant of 109,856 shares, 3-Jun-2026), not open-market purchases.
• INTERPRETATION: The insider picture is routine planned selling of vested equity into strength — not a conviction signal in either direction. For an FPI, open-market discretionary insider buys are rare, and there are none of note here; equally, the 144 sales are small and vesting-driven, not a red flag. Do not overstate this. The only “insider” of consequence is KO’s ~19–20% strategic stake (via European Refreshments) — a franchisor anchor, not a tradeable float, and its presence is a structural feature, not a bullish/bearish tell.

8.3 One-time items — reported vs comparable EPS gap (run-rate distortion)

• FACT: FY2025 reported diluted EPS €4.26 (+38.3%) vastly overstates underlying progress; comparable diluted EPS €4.11 (+6.2%) is the true run-rate (results 6-K). The gap runs the other way from prior years: FY2024 reported EPS was depressed (€3.08) by acquisition/integration and inventory fair-value step-up costs tied to CCBPI, so the FY24→FY25 reported jump is optically huge. Comparable EPS ~€3.87 (FY24) → €4.11 (FY25) is the honest ~+6% picture. Use the comparable series for run-rate and the reported series only for statutory cash tax/coverage. Anyone anchoring on “+38% EPS growth” is being fooled by the FY24 base.
• FACT: Effective tax rate is a genuine, structural headwind: reported ETR 23% FY25 (25% FY24); comparable ETR 26% FY25, guided ~26% FY26 (20-F; results 6-K). A rising comparable ETR toward ~26% is a real ~3-point drag on forward comparable-EPS growth versus the FY25 base — a reason the FY26 operating-profit guide of +7% converts to only mid-single-digit EPS growth.

8.4 Environmental / demand headwinds

• European volume softness (FACT/INTERPRETATION): Europe (~three-quarters of revenue) volume was −0.2% FY2025; the region is a low-growth, cost-of-living-pressured, high-regulation base. Growth is entirely price/mix. This is the structural ceiling on the algorithm.
• Indonesia weakness (FACT): “double-digit decline in Indonesia reflecting a weaker consumer” (results 6-K) — the one clear soft spot in the otherwise-additive APAC story, and a watch-item for CCBPI/API goodwill.
• Commodity & FX (FACT/ASSUMPTION): FY26 cost-of-sales-per-case guided +~1.5% with commodities ~80% hedged; sugar/PET/aluminium and sugar taxes are the input-cost swing factors (20-F). Manageable and hedged, but margin depends on pricing staying ahead of input inflation — the risk if consumer resistance to price rises builds.
• Packaging / deposit-return-scheme (DRS) regulation (INTERPRETATION): rolling DRS and packaging-EPR regimes across CCEP’s European markets raise cost-to-serve and working-capital complexity; recyclable-content and reuse mandates are a persistent, low-grade regulatory tax on a packaged-beverage bottler. Not thesis-breaking, but a structural cost creep.
• Suntory alcohol exit (FACT): end of Suntory alcohol distribution in Australia (Jun-25) and NZ (Dec-25) trims ~0.5% of group revenue in FY26 — a small, disclosed, self-inflicted headwind (results 6-K).
• Leadership (FACT): CEO Damian Gammell and the core team remain in place; no destabilizing C-suite/board turnover in the window — continuity through the integration and deleveraging is a modest positive.

Changes-and-headwinds verdict: Net thesis-neutral-to-slightly-strengthening on structure, capping on growth. The portfolio is bigger, better balanced, deleveraged and now cash-returning — all durable positives. But the environment (flat European volume, weak Indonesia, rising tax rate, packaging regulation, hedged-but-real input inflation) confirms CCEP as a low-single-digit organic grower dressed up by price/mix and M&A — precisely the profile that does not comfortably support a 97th-percentile, franchisor-like valuation. The business got better; the entry price got worse.

9. Risk Analysis

The risk set for CCEP is unusually structural rather than idiosyncratic: the biggest exposures are baked into what CCEP is — the capital-heavy, low-margin, franchisee half of someone else’s brand system, operating across a dozen currencies, none of them the USD in which the ADR is quoted. The matrix below rates likelihood and impact over a 2–3 year horizon.

Risk prose. KO dependence (1) is the master risk and the reason CCEP structurally earns a bottler’s ~10% ROIC rather than a franchisor’s mid-teens: KO owns the brands, sets concentrate price, and holds a ~19–20% stake that both aligns and constrains. Every euro of CCEP margin is negotiated against a partner that captures the higher-return half of the chain — a permanent ceiling on economics, not an event risk. Commodity + FX (2, 3) are the volatility engine: PET, aluminium and sugar drove the 2022 margin squeeze, and because the stock is EUR-earnings translated into a USD quote, a US holder carries a currency bet layered on top of an operating bet — the ~$106 print embeds a favorable recent EUR/USD as much as it embeds operations. European weakness + sugar/GLP-1 (4, 5) attack the same soft spot: a mature core where volume is already flat and the entire algorithm leans on price/mix — if regulation or GLP-1 accelerates the CSD-volume drift while the consumer weakens, pricing power is tested precisely when it’s most needed. DRS/plastics (6) is a certain, grinding cost, not a tail. Leverage (7) is comfortable at ~2.7x but caps optionality. EM (8) and integration (10) are the growth-versus-risk trade CCEP has chosen. Aggregate verdict: MEDIUM. No single existential/catastrophic risk (unlike a wildfire utility or a single-drug biotech) — the franchise, the diversification and the low beta genuinely damp downside — but the stack of structural constraints (franchisor ceiling, FX, mature-market volume, regulation) means the business cannot out-earn its ~10% ROIC design, and the current price leaves little cushion if two or three of these bite at once.

10. Valuation

Where the stock trades. At $106.61 (2026-07-02), CCEP carries a market cap of ~$47.0B and an enterprise value of ~$57–58B (adding ~$10.7B net debt). On the numbers, and correcting for a data trap: CCEP earns and reports EPS in EUR while the stock is quoted in USD, so any USD “P/E” silently embeds the EUR/USD rate — and the third-party feed’s headline “P/E ~18x / TTM EPS ~$5.90” is stale and should be discarded (it reconciles to neither the reported nor the comparable EUR figure). Computed honestly off the verified FY2025 figures at ~1.17 EUR/USD: comparable diluted EPS €4.11 ≈ ~$4.8 → P/E ~22x, and reported diluted EPS €4.26 ≈ ~$5.0 → P/E ~21x. So the honest earnings multiple is ~21–22x, not 18x. Other lenses: EV/EBITDA ~13x (on real EBITDA of ~€3.7B ≈ ~$4.3B), EV/EBIT ~17.7x, P/S 1.70x, FCF yield ~4.5% (comparable FCF €1,836m, capex incl. leases), dividend yield 2.25%, and a ~5% total shareholder yield once the ~€1B annual buyback is layered on the dividend. (P/B “5.78x” is a broken lens — tangible equity is negative ~−€8.7B / −€19/share on €17B of acquisition goodwill+franchise intangibles; ignore it.)

The headline — richest-ever on its own history. The single most important valuation datum is the own-history percentile stack: composite 97.8th, P/E 93.8th, P/B 99.8th, P/S 99.8th. On every metric the stock sits at or within a whisker of the most expensive it has ever been in its own multi-year range — and because the percentile engine used the stale ~$5.90 EPS, the true P/E percentile on the corrected ~22x is, if anything, even higher than 93.8th. This is not a “cheap defensive bottler” anymore; the 2022→2026 move re-rated the multiple as much as it grew the earnings. (P/B at 99.8th is a mechanical artifact — negative tangible book — so lean on the P/S 99.8th and P/E percentiles as the real tell. Source: AZI valuation_index, accessed 2026-07-04.)

Comp table — CCEP is cheaper than the franchisor but RICHER than its fellow bottlers.

*CCEP P/E ~22x on comparable EPS (€4.11); ~21x on reported (€4.26), at ~1.17 EUR/USD. Sources: KO/KDP/MNST prior the author reports; CCH.L valueinvesting.io/Yahoo (~10.25x EV/EBITDA, P/E 19.4x, accessed 2026-07-04); KOF simplywall.st/Seeking Alpha (fwd EV/EBITDA ~7.5x, P/E ~16x, accessed 2026-07-04).

Read the table carefully. The lazy bull frame — “CCEP is cheap, it trades at ~13x EV/EBITDA vs KO’s ~22–23x” — is correct but misleading. The bottler discount to the franchisor is deserved and permanent: CCEP earns ~10.5% ROIC on a capital-heavy, 13% operating-margin business, while KO earns mid-to-high-teens ROIC on a 28.7%-margin, asset-light one. A bottler should trade at roughly half the franchisor’s EV/EBITDA — and it does. The right comparison is CCEP versus its own kind, and there the picture inverts: at ~13x EV/EBITDA, CCEP trades at a ~25–75% premium to CCH.L (~10.3x) and KOF (~7.5x) — two bottlers with broadly similar ~10–12% ROIC economics. (INTERPRETATION) That premium is partly justified — CCEP is the largest, most developed-market-weighted, lowest-EM-risk bottler with the best balance sheet and a genuine buyback — but it is a premium within the bottler complex, layered on top of a richest-ever own-history multiple. The question is therefore not “is a bottler cheaper than KO?” (yes, correctly) but “does CCEP deserve its own richest-ever re-rating AND a premium to CCH/KOF simultaneously?”

Reverse-DCF / embedded expectations. Two framings, deliberately, because they disagree and the disagreement is the thesis.

• Absolute FCF perpetuity (the bull’s friend). CCEP throws off ~€1.84B comparable FCF (~$2.15B). Because beta is ~0.29, a defensible cost of capital is low — take ~7%. Solving EV = FCF·(1+g)/(r−g) at EV ~$57.5B and FCF ~$2.15B implies embedded perpetual FCF growth of only ~3.1% (at r=7%) to ~3.6% (at r=7.5%). That is roughly inflation-plus-a-touch growth — beatable by a business running a mid-single-digit comparable-EPS algorithm plus buyback. On this lens CCEP is full but not absurd: the low-beta, low-WACC characteristic does real work.
• Comparable-EPS bridge (the honest operator’s view). At ~$106.6 and comparable EPS of ~$4.8 (€4.11), you pay ~22x for an algorithm of mid-single-digit comparable-EPS growth (~6–8%, of which ~1–2 pts is buyback and against a ~26% rising-tax-rate headwind) + 2.25% dividend. Total prospective return ~8–10% if the multiple holds. The catch: the 2022→2026 ~2.7x move was ~half re-rating (EV/EBITDA ~9–10x → ~13x) and half earnings. That re-rating leg is now spent — the stock is at the 97.8th own-history percentile — so future return must come from the algorithm alone, with the multiple a headwind, not a tailwind, if it mean-reverts toward the bottler-peer 10–11x.

Scenarios (illustrative, no price target).

What the market is underwriting correctly vs incorrectly. Correct: the durability of the Coca-Cola system demand, the diversification across 31 markets, the low-beta defensive character, the improving ROIC (6.1%→10.5% over five years), and the shift to a genuine capital-return story (first buyback + growing dividend). Where the price is aggressive (INTERPRETATION): it extrapolates the re-rating — the move from a bottler-peer ~10x to ~13x EV/EBITDA and to richest-ever own-history percentiles — as if it were a new permanent multiple, when the underlying business is still a ~10% ROIC, mid-single-digit-grower structurally capped by KO’s concentrate pricing. The market is paying a quality-compounder multiple for bottler economics. Verdict (embedded expectations): FULLY PRICED. On an absolute low-WACC FCF basis the embedded ~2.5–3.5% growth is beatable, so this is not a short and not a bubble; but at the 97.8th own-history percentile and a premium to CCH/KOF, the easy money (the re-rating) is made, the margin of safety is thin, and forward return is now essentially the algorithm plus ~5% shareholder yield — a good business at a price that already assumes the good news continues.

11. Variant Perception

Consensus view. The Street and the tape treat CCEP as a “sleep-well” low-volatility staples compounder — the world’s largest Coca-Cola bottler, diversified across 31 developed and emerging markets, delivering a dependable mid-single-digit comparable-EPS algorithm, an improving ROIC, a growing dividend now topped with a buyback, and a beta of ~0.29 that makes it a defensive core holding. The factor data corroborates why consensus loves it: realized beta ~0.29, model market beta ~0.51, Consumer Staples loading ~+0.42, a large positive LowVolatility loading (~+0.24), essentially zero Momentum (+0.02) and negative Growth (−0.06) — this is empirically a low-vol, defensive-staples name, not a growth or momentum stock by construction. Yet its behavior has been momentum-like: 3-year annualized return +15.6% at a Sharpe of 0.69 with a max drawdown of only −18.2%, and it now sits near its relative-strength peak (rs_peak −2.4, rs_12m +17.5). Consensus has been paid handsomely for owning “safety,” and the safety has behaved like a winner. (Source: FactorsToday loadings/leaderboard, accessed 2026-07-04.)

Strongest bull case. CCEP is a structurally de-risked, self-improving bottler at the start of a capital-return era. ROIC has climbed 6.1%→10.5% in five years; the Amatil and CCBPI deals added developed-market Australia and EM growth (Philippines/Indonesia) without wrecking the balance sheet (~2.7x); the first €1B buyback signals a management finally returning excess cash; and the low-beta, EUR-earnings profile is exactly what allocators want in a late-cycle, uncertain-rate world. If European volume merely stabilizes while EM inflects and margins add 50–100bps, an ~8–10% comparable-EPS algorithm plus a ~5% shareholder yield compounds at low-double-digits with bond-like drawdowns — and the multiple stays re-rated because the market permanently recognizes CCEP as a quality staples name, not a cyclical bottler.

Strongest bear case. You are paying a richest-ever multiple (97.8th own-history composite) — and a premium to fellow bottlers CCH.L/KOF — for economics that are permanently capped at ~10% ROIC by KO’s control of the concentrate price. The 2022→2026 ~2.7x return was roughly half re-rating; that leg is spent, so forward return must come from a mid-single-digit algorithm that leans almost entirely on price/mix in a mature, weakening European consumer facing sugar taxes, DRS cost, GLP-1 demand drift and hard-discounter private label. Layer on FX (a US holder’s return is EUR-translated and can reverse), ~2.7x leverage, negative tangible book, and EM/integration execution — and the low beta that everyone loves may simply mean the stock de-rates slowly rather than crashes, delivering flat-to-negative real return from here as the multiple mean-reverts toward the 10–11x its bottler peers command. The “safety” is a crowded, richly-priced consensus, not a margin of safety.

The 3–5 assumptions that matter most.

1. The re-rating is permanent, not cyclical — that ~13x EV/EBITDA (vs CCH ~10.3x / KOF ~7.5x) is the new normal for a DM bottler, not a peak to be given back.
2. Pricing power holds through European consumer weakness — that price/mix keeps delivering ~mid-single-digit revenue even as volume stays flat-to-down and regulation bites.
3. KO stays a benign partner — no adverse shift in concentrate pricing or franchise terms that compresses CCEP’s already-thin 13% operating margin.
4. EM (Philippines/Indonesia) inflects into a real growth engine without FX/political value destruction or integration disappointment.
5. EUR/USD and rates don’t reverse the tailwind embedded in the USD-quoted ~$106 price.

What would falsify each side. Falsify the bull: two-to-three quarters of negative European volume that price/mix cannot offset (comparable-EPS growth slips below ~4%), OR the multiple compresses toward the CCH/KOF 10–11x band on any growth wobble — proving the re-rating was cyclical. Falsify the bear: EM volume inflects and DM stabilizes with margins expanding and the buyback accelerating, delivering ~8–10% comparable-EPS growth that the market rewards by holding the premium multiple — proving CCEP has genuinely graduated from “bottler” to “quality staples compounder.”

Verdict (Variant Perception). The variant view is that consensus is mildly offsides on “safe defensive growth.” The factor read is unambiguous — this is a low-beta, low-vol, zero-momentum-by-construction staples name that has behaved like momentum and now sits at its relative-strength peak and its richest-ever valuation. That combination — a defensive stock priced like a winner, at the top of its own history and at a premium to its direct comps — is precisely where “safety” becomes crowded and the asymmetry turns unfavorable. The business is genuinely good and genuinely de-risked; the price has already paid CCEP for the transformation. The mispricing, if any, is not a crash risk (the low beta is real) but a return-of-capital-masquerading-as-a-compounder risk: the easy re-rating is done, and consensus is underwriting its continuation.

12. Fact vs. Interpretation Table

13. Open Questions

1. Impairment headroom. What discount rate and terminal-volume assumptions underpin the annual goodwill/franchise-rights impairment test, and how much headroom exists in the weak Indonesia and low-growth European CGUs? The €17.0B of intangibles is the accumulated M&A premium and would vaporize reported equity if a major territory’s volume structurally declines. (Fact-seeking; unresolved from public disclosure.)
2. Concentrate-pricing trajectory. How much of CCEP’s price/mix does incidence concentrate pricing recapture each year, and is TCCC’s concentrate-price posture stable or tightening? This is the master governor on CCEP’s margin and is not quantified in disclosure.
3. Philippines/Indonesia inflection timing. When does the EM leg become a durable volume engine rather than a volatile drag, and is the 40% CCBPI minority (held with Aboitiz) a future full-buyout call on more capital?
4. Franchise-agreement renewal terms. What are the actual renewal economics and any performance conditions in the current bottler agreements, and when do the key territories come up for renewal? The public 20-F describes the structure but not the commercial specifics.
5. Pricing durability vs. the European consumer. Can price/mix keep delivering ~mid-single-digit revenue if European volume stays negative and hard-discounter private label keeps gaining — i.e., where is the point at which further price destroys volume?
6. FX exposure to the US holder. How much of the ~$106 quote reflects a favorable recent EUR/USD, and what is the translation sensitivity of comparable EPS to a 10% EUR move against the basket of GBP/AUD/IDR/PHP/NOK/SEK?

14. What Must Be True

For the bull case to be right (the multiple holds and CCEP compounds low-double-digits):

• Europe stabilizes and EM inflects. Mature-Europe volume moves from ~−0.2% to flat-or-positive and Philippines/Indonesia deliver durable volume growth, lifting the organic algorithm toward ~4–6% revenue and ~8–10% comparable EPS.
• Pricing power survives the consumer. Price/mix keeps offsetting flat volume and rising sugar-tax/DRS/EPR costs without triggering volume destruction, and incidence recapture stays stable.
• The re-rating proves permanent. The market keeps valuing CCEP as a “quality staples compounder” at ~12–13x EV/EBITDA rather than reverting toward the CCH/KOF 10–11x bottler band.
• Falsification test: two-to-three consecutive quarters of negative European volume that price/mix cannot offset (comparable-EPS growth below ~4%), or any multiple compression toward 10–11x on a growth wobble, falsifies the bull and proves the re-rating was cyclical.

For the bear case to be right (a slow de-rate to flat-to-negative real return):

• The algorithm stalls at the low end. European volume stays negative, EM stays volatile, and comparable-EPS growth settles at ~2–4% against the ~26% tax step-up and higher refinancing costs.
• The multiple mean-reverts. ~13x EV/EBITDA and the 97.8th own-history percentile give way toward the bottler-peer 10–11x, converting the past tailwind into a multi-year headwind.
• FX and regulation compound. An EUR/USD reversal erodes the US holder’s return while sugar taxes, DRS and EPR keep grinding the bottler’s cost base.
• Falsification test: a durable EM volume inflection with DM stabilization and +50–100 bps of margin, delivering ~8–10% comparable-EPS growth that the market rewards by holding the premium multiple, falsifies the bear and proves CCEP has genuinely graduated from bottler to quality compounder.

The pivot for both: whether CCEP’s growth is an owned volume engine (bull) or price/mix-plus-buybacks masking a stagnant mature core (bear) — and whether today’s richest-ever multiple is a new permanent rating or a peak to be given back. At ~$106 the price already pays for the bull; the burden of proof sits with the volume engine that CCEP does not fully control.

15. Source Appendix

Primary filings (SEC EDGAR, CIK 0001650107) — foreign private issuer, files 20-F/6-K in EUR under IFRS

• CCEP FY2025 Annual Report on Form 20-F (cce-20251231.htm), filed 2026-03-13 — business, segments, franchise agreements, risk factors, financial statements, remuneration report, goodwill/intangibles, impairment testing. Mirrored to output/CCEP/sources/20-F/.
• CCEP FY2024 Form 20-F (cce-20241231.htm), filed 2025-03-21 — prior-year comparison; CCBPI acquisition accounting.
• FY2025 full-year results 6-K, 2026-02-17 — comparable diluted EPS €4.11, comparable operating profit €2,808M, net debt/EBITDA 2.7x, comparable FCF €1,836M, DPS €2.04, first/new €1.0B buyback, FY2026 guidance.
• Q1 2026 trading update 6-K, 2026-04-28 — revenue €5,001M +6.7% comparable FXN; guidance reaffirmed; extra selling days.
• Buyback 6-Ks — 2026-02-17 (€1.0B programme announced), 2026-07-02 (tranche 1 €500M completed 24-Apr-2026; tranche 2 commenced 6-Jul-2026); weekly transparency-directive transaction notices through 2026.
• AGM results 6-K, 2026-05-29 — all resolutions passed; 443.2M shares in issue; interim dividend approved.
• 2025 Half-Year Report 6-K, 2025-08-06.
• 5-year EDGAR corpus (285 filings): 213 × 6-K, 52 × Form 144 (routine planned insider sales), 5 × 20-F, plus CORRESP/UPLOAD/8-A12B. Reviewed for the insider read and material-event timeline.

Management commentary (treated as hypothesis, validated against filings)

• CCEP Q4/FY2025 earnings-call transcript, 2026-02-17 (ROIC.ai) — CEO Damian Gammell, CFO Ed Walker: incidence concentrate pricing; ~90% 3-year TSR; ~€4B returned over 3 years; €1.0B 2026 buyback; comparable ROIC +70 bps to ~11%; net debt/EBITDA ~2.7x; 2026 tax rate ~26%; softer Indonesia and Germany/France (sugar tax) volumes; “strategic portfolio changes now largely behind us.”

Quantitative data

• ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/credit/per-share ratios, enterprise value and valuation multiples (FY2020–FY2025), reconciled to the 20-F.
• AZI price history CSV (azitrading.com, accessed 2026-07-04) — 5-year adjusted OHLCV, EMAs, beta/alpha; and AZI valuation_index own-history percentiles (composite 97.8th; P/E 93.8th; P/B 99.8th; P/S 99.8th).
• FactorsToday factor model (factorstoday.com/api, accessed 2026-07-04) — stock loadings (LowVol +0.24, Consumer Staples +0.42, Momentum +0.02, Growth −0.06), leaderboard (y3 return +15.6%, Sharpe 0.69, max DD −18.2%), stock-info (beta 0.29, rs_12m +17.5, rs_peak −2.4).
• AZI news feed (accessed 2026-07-04) — thin (FPI); Wells Fargo initiated Overweight 2026-06-12 (Benzinga).

Peer / cross-read (public comps)

• The Coca-Cola Company (KO) FY2025 10-K (franchisor value-chain comparison); Keurig Dr Pepper (KDP), Monster Beverage (MNST), Constellation Brands (STZ) public filings — for the beverage comp set.
• Coca-Cola HBC (CCH.L) — valueinvesting.io / Yahoo Finance (~10.25x EV/EBITDA, P/E 19.4x, accessed 2026-07-04).
• Coca-Cola FEMSA (KOF) — simplywall.st / Seeking Alpha (fwd EV/EBITDA ~7.5x, P/E ~16x, accessed 2026-07-04).

Industry / regulatory (public secondary)

• Euromonitor / Statista / NIQ (2025) — Western European soft-drink volume growth ~1–2%, per-capita consumption, private-label share (~44% of new launches). Accessed via web search 2026-07-04.
• EU Packaging & Packaging Waste Regulation; national deposit-return-scheme rollouts; GB/France sugar-tax changes — trade press and CCEP 20-F risk factors.

Framework references

• Bruce Greenwald & Judd Kahn, Competition Demystified (moat taxonomy: local-scale/captivity advantage).
• Edward Chancellor (ed.), Capital Returns / Marathon Asset Management (supply-side capital-cycle lens).

All non-obvious facts are cited inline with source and date. Where management commentary and external evidence could diverge, filings and financial data were treated as authoritative and the commentary as hypothesis. ROIC.ai, AZI and FactorsToday are third-party aggregated/estimated data, reconciled to the primary 20-F where material.

APPENDIX A — Standard Diligence Questionnaire

Coca-Cola Europacific Partners plc (NASDAQ: CCEP) — supplemental to the analysis above. Fact/Interpretation/Assumption labels where material.

General

What thoughtful questions have other investors asked about this company? The core debate is whether CCEP has “graduated” from a cyclical, capital-heavy bottler into a durable quality-staples compounder that deserves its richest-ever multiple, or whether the 2022→2026 re-rating simply borrowed forward return that must now be given back. Sophisticated investors focus on: (1) how much of CCEP’s price/mix is recaptured upstream by KO’s incidence concentrate pricing; (2) the durability of European pricing power against flat-to-negative volume and rising sugar taxes; (3) whether the Philippines/Indonesia EM leg is a real volume engine or a volatile drag (Indonesia fell double-digits in 2025); (4) the impairment risk in the €17B of acquisition goodwill/franchise intangibles; and (5) whether buying back stock at the 97.8th own-history percentile is sensible capital allocation. (Interpretation, synthesized from the analysis.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Nearer a high than a low: margins have expanded steadily (operating margin 10.7%→13.4% since 2020), FY2025 carried an unusually strong ~55% incremental operating margin (not a run-rate), and the valuation multiple is at its richest ever. Comparable EPS growth of ~6% is a normalized, not depressed, figure. (Interpretation.)

Driven by the external environment or internal actions? Predominantly internal — pricing/revenue-growth-management, efficiency programs, Amatil/CCBPI synergy realization, deleveraging, and buybacks are all management-controlled. The external environment (European consumer, commodities, FX, regulation) is currently a mild headwind, not a tailwind. (Interpretation.)

How stable are revenues? Very stable — habitual, daily, low-ticket consumption across 31 markets and ~4M outlets, beta ~0.29, y3 max drawdown only −18%. System volume has declined only rarely. But stability ≠ growth: the mature European core (~74% of revenue) is volume-stagnant.

Outlook for products/services? Durable category demand; the mix is shifting toward zero-sugar, energy (Monster distribution), water, coffee (Costa RTD) and RTD alcohol (Jack Daniel’s & Coca-Cola), partly hedging the secular drift away from full-sugar CSDs. (Fact/Interpretation; Q4 2025 call.)

How big will this market be — growing, shrinking, domestic or international? International (Europe + Asia-Pacific/SE Asia). Western Europe is mature (~1–2% volume growth); Philippines/Indonesia offer genuine per-capita volume headroom. Net: a low-single-digit-volume, price/mix-led global category. (Fact; Euromonitor 2025.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Broadly stable and rational among branded players (Coca-Cola vs PepsiCo systems compete on execution, not destructive price wars), but more competitive at the value end from hard-discounter private label (~44% of new European launches). Retailer concentration is a persistent, adverse structural feature. (Fact/Interpretation.)

How profitable is the business (ROIC, ROE)? ROE 22.0%, but comparable ROIC only ~11% (reported ~10.9%). The gap is financial leverage + a goodwill-inflated equity base. ROIC clears an estimated ~7% WACC by only ~3–4 points — value-creating but thin. (Fact; results 6-K + assumption on WACC.)

How profitable is the industry — competitors, barriers to entry? The bottling layer earns bottler-level returns (~10% ROIC) because the profit pool skews to the brand/concentrate owner (KO: 28.7% blended / 59% concentrate margin). Barriers to entry within a territory are high (exclusive franchise + distribution density), but returns are capped from above by the franchisor and from below by retailers/commodities/regulation. (Fact/Interpretation.)

Can the business be easily understood? Yes — a franchised bottler: buy concentrate, add water/sugar/packaging, distribute cold to ~4M outlets. The one subtlety is incidence concentrate pricing. (Fact.)

Can it be undermined by foreign low-cost labor? No — production and distribution are inherently local (>90% made locally; the moat is physical last-mile density). (Fact.)

Do brands matter? Decisively — but the brands belong to TCCC and Monster, not CCEP. CCEP monetizes others’ brand pull via distribution; it does not own the intangible. (Fact/Interpretation.)

What is the nature of competition? Execution, innovation, marketing spend and channel/cooler placement — rational branded competition plus a value-end private-label threat. (Interpretation.)

Customers’ switching costs? For the retail/on-premise customer, moderate (CCEP’s cold-drink route-to-market, coolers and service are sticky); for the consumer, essentially none (brand loyalty is TCCC’s asset). (Interpretation.)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The genuine asset — the exclusive KO franchise relationship and distribution network — is only partly captured as €12.5B of indefinite-lived franchise/bottling intangibles; its going-concern value rests on the cash it generates, not book. (Interpretation.)

Off-balance-sheet liabilities? Leases are capitalized under IFRS 16 (and CCEP’s FCF definition deducts lease principal). Pension obligations, DRS/EPR compliance costs and the 40% CCBPI minority (a potential future buyout call) are the items to watch. No disclosed material off-balance-sheet financing. (Fact/Open Question.)

How conservative is the accounting? Reasonable, but note the reported-vs-comparable EPS gap (reported €4.26 vs comparable €4.11) and monitor that “comparable” adjustments (which strip acquisition/integration costs) stay honest. Long-term incentive pay is graded partly on comparable EPS. (Fact/Interpretation.)

How CapEx-hungry is the business? Moderately — ~5% of revenue including leases (plants, fleet, coolers, PET lines). Asset-heavier than the franchisor relative to the margin it supports; this is the cost of owning the capital-intensive half of the system. (Fact.)

Capital Allocation & Management

How much FCF, and how is it used? Comparable FCF ~€1.84B (~4.5% yield). Used for a growing ~50%-payout dividend (~€0.9B) and, since FY2025, buybacks (~€2B across FY2025–26). Philosophy: integrate → deleverage to ~2.7x → return cash. (Fact.)

Significant acquisitions recently? Coca-Cola Amatil (2021, ~$6.6B, APAC) and Coca-Cola Beverages Philippines (Feb 2024, ~$1.8B for 60%). Both strategically defensible; integration is the swing factor. (Fact/Interpretation.)

Buying back shares? Yes — a genuine inflection: €1,045M in FY2025 plus a €1.0B 2026 programme (all cancelled; count 456M→443M). Critique: executed at the richest own-history multiple. (Fact/Interpretation.)

Issuing large amounts of stock to insiders? No — SBC is negligible (~€47M/yr, <0.25% of revenue). (Fact.)

Compensation policy / incentives? Long-term pay tied to comparable diluted EPS + comparable ROIC (with a CO₂e-per-litre modifier) — appropriately returns-focused for a leveraged acquirer, guarding against value-destructive M&A. FY2027 LTIP EPS target range €4.28–€5.17 implies only mid-single-digit CAGR — realistic, not heroic. (Fact; 20-F remuneration report.)

Motivations of management? Continuity (CEO Damian Gammell and team in place through integration/deleveraging); incentives aligned to returns and EPS. No empire-building signals; the recent behavior is returning cash rather than chasing deals. (Interpretation.)

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? It is the ordinary share of a UK-domiciled plc, listed on NASDAQ (and Euronext Amsterdam, LSE, Spanish exchanges) — a foreign private issuer filing 20-F/6-K, reporting in EUR under IFRS. Not an MLP/K-1. US holders bear EUR/USD translation risk on an EUR-earnings business. (Fact.)

Dividend policy? Progressive, ~50% of comparable EPS; DPS €1.67→€2.04 over four years; ~2.25% yield. (Fact.)

How profitable is the business? ~35% gross / ~13% operating / ~9% net margin; ROE 22%, ROIC ~11%. Good for a bottler; far below the franchisor. (Fact.)

Is net income diverging from cash from operations? No adverse divergence — OCF ~€2.95B vs net income €1.94B (OCF/NI ~1.5x), healthy and consistent, with high D&A add-back and disciplined working capital. (Fact.)

Risks & Downside

What factors would cause the stock to decline? Multiple mean-reversion toward bottler-peer 10–11x EV/EBITDA; European volume staying negative with price/mix unable to offset; a rising tax rate and refinancing costs capping EPS; an EUR/USD reversal for US holders; adverse KO concentrate-pricing or franchise-terms shift; EM (Indonesia) weakness or a goodwill impairment. (Interpretation.)

Risk of a catastrophic loss? Low. Investment-grade (A3/A-), ~10x interest cover, diversified 31-market demand, low beta, ~5% shareholder yield. The realistic bear is a slow de-rate to flat-to-negative real return, not a wipeout. (Interpretation.)

Chance of a total loss? Negligible over any reasonable horizon — a systemically important, cash-generative Coca-Cola anchor bottler with a strategic KO stake. (Interpretation.)

Recent News & Events

Has the business environment changed recently? Yes, modestly: European volume softened (Germany/France on higher sugar taxes), Indonesia weakened, the 2026 tax rate steps up to ~26%, and packaging/DRS regulation is rolling out — all capping the growth algorithm. Offsetting: deleveraging complete, capital-return inflection underway, FTSE UK index inclusion (Mar 2025), Wells Fargo initiated Overweight (Jun 2026). (Fact; results 6-K, news feed.)

Significant acquisitions? CCBPI Philippines (Feb 2024) is the most recent; “strategic portfolio changes now largely behind us” per management. Small self-inflicted headwind: exit of Suntory alcohol distribution in Australia/NZ (2025). (Fact.)

Change in accounting policies? None material disclosed; standard IFRS. Monitor the comparable-vs-reported EPS bridge. (Fact.)

Recent changes — new markets, facilities, management? Philippines added (2024); >€900M invested in capacity, coolers, technology and digital; leadership stable. (Fact.)

APPENDIX B — Source Appendix

Primary filings (SEC EDGAR, CIK 0001650107) — foreign private issuer, files 20-F/6-K in EUR under IFRS

• CCEP FY2025 Annual Report on Form 20-F (cce-20251231.htm), filed 2026-03-13 — business, segments, franchise agreements, risk factors, financial statements, remuneration report, goodwill/intangibles, impairment testing. Mirrored to output/CCEP/sources/20-F/.
• CCEP FY2024 Form 20-F (cce-20241231.htm), filed 2025-03-21 — prior-year comparison; CCBPI acquisition accounting.
• FY2025 full-year results 6-K, 2026-02-17 — comparable diluted EPS €4.11, comparable operating profit €2,808M, net debt/EBITDA 2.7x, comparable FCF €1,836M, DPS €2.04, first/new €1.0B buyback, FY2026 guidance.
• Q1 2026 trading update 6-K, 2026-04-28 — revenue €5,001M +6.7% comparable FXN; guidance reaffirmed; extra selling days.
• Buyback 6-Ks — 2026-02-17 (€1.0B programme announced), 2026-07-02 (tranche 1 €500M completed 24-Apr-2026; tranche 2 commenced 6-Jul-2026); weekly transparency-directive transaction notices through 2026.
• AGM results 6-K, 2026-05-29 — all resolutions passed; 443.2M shares in issue; interim dividend approved.
• 2025 Half-Year Report 6-K, 2025-08-06.
• 5-year EDGAR corpus (285 filings): 213 × 6-K, 52 × Form 144 (routine planned insider sales), 5 × 20-F, plus CORRESP/UPLOAD/8-A12B. Reviewed for the insider read and material-event timeline.

Management commentary (treated as hypothesis, validated against filings)

• CCEP Q4/FY2025 earnings-call transcript, 2026-02-17 (ROIC.ai) — CEO Damian Gammell, CFO Ed Walker: incidence concentrate pricing; ~90% 3-year TSR; ~€4B returned over 3 years; €1.0B 2026 buyback; comparable ROIC +70 bps to ~11%; net debt/EBITDA ~2.7x; 2026 tax rate ~26%; softer Indonesia and Germany/France (sugar tax) volumes; “strategic portfolio changes now largely behind us.”

Quantitative data

• ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/credit/per-share ratios, enterprise value and valuation multiples (FY2020–FY2025), reconciled to the 20-F.
• AZI price history CSV (azitrading.com, accessed 2026-07-04) — 5-year adjusted OHLCV, EMAs, beta/alpha; and AZI valuation_index own-history percentiles (composite 97.8th; P/E 93.8th; P/B 99.8th; P/S 99.8th).
• FactorsToday factor model (factorstoday.com/api, accessed 2026-07-04) — stock loadings (LowVol +0.24, Consumer Staples +0.42, Momentum +0.02, Growth −0.06), leaderboard (y3 return +15.6%, Sharpe 0.69, max DD −18.2%), stock-info (beta 0.29, rs_12m +17.5, rs_peak −2.4).
• AZI news feed (accessed 2026-07-04) — thin (FPI); Wells Fargo initiated Overweight 2026-06-12 (Benzinga).

Peer / cross-read (public comps)

• The Coca-Cola Company (KO) FY2025 10-K (franchisor value-chain comparison); Keurig Dr Pepper (KDP), Monster Beverage (MNST), Constellation Brands (STZ) public filings — for the beverage comp set.
• Coca-Cola HBC (CCH.L) — valueinvesting.io / Yahoo Finance (~10.25x EV/EBITDA, P/E 19.4x, accessed 2026-07-04).
• Coca-Cola FEMSA (KOF) — simplywall.st / Seeking Alpha (fwd EV/EBITDA ~7.5x, P/E ~16x, accessed 2026-07-04).

Industry / regulatory (public secondary)

• Euromonitor / Statista / NIQ (2025) — Western European soft-drink volume growth ~1–2%, per-capita consumption, private-label share (~44% of new launches). Accessed via web search 2026-07-04.
• EU Packaging & Packaging Waste Regulation; national deposit-return-scheme rollouts; GB/France sugar-tax changes — trade press and CCEP 20-F risk factors.

Framework references

• Bruce Greenwald & Judd Kahn, Competition Demystified (moat taxonomy: local-scale/captivity advantage).
• Edward Chancellor (ed.), Capital Returns / Marathon Asset Management (supply-side capital-cycle lens).

All non-obvious facts are cited inline with source and date. Where management commentary and external evidence could diverge, filings and financial data were treated as authoritative and the commentary as hypothesis. ROIC.ai, AZI and FactorsToday are third-party aggregated/estimated data, reconciled to the primary 20-F where material.